The company’s shift involves a $12 million acquisition of commercial rights to Rebyota and Clenpiq from Ferring Pharmaceuticals, a move fully funded by the recent $18 million divestment of its Talicia interest. Rebyota, an FDA-approved fecal microbiota transplant for recurrent C. difficile infections, and Clenpiq, a low-volume bowel preparation, generated a combined $37.5 million in 2025 net sales. RedHill CEO Dror Ben-Asher stated that these assets provide the necessary control to scale operations and identify further complementary products for their existing U.S. GI infrastructure.

Beyond commercial operations, RedHill is advancing its R&D pipeline, emphasizing oncology and infectious disease. Opaganib, the company’s lead candidate, has secured U.S. FDA rare pediatric disease designation for neuroblastoma, a milestone that could grant the company a Priority Review Voucher. Simultaneously, the firm continues to develop RHB-204 for Crohn’s disease and RHB-102 for GI-associated intolerances. Financially, the company reported a net loss of $6.1 million for the first half of 2026, though management maintains that the streamlined structure and new revenue-generating assets position the firm for improved operational efficiency in the coming quarters.